Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImpedimedASX:IPD -16.67% Debt-to-Equity is 2.39 as of Dec. 2025, which is 7867% above its 10-year median of 0.03. The stock has 6 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Impedimed ranks worse than 95.47% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Impedimed's Debt-to-Equity or its related term are showing as below:
ASX:IPD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 2.39
Current: 2.39
During the past 13 years, the highest Debt-to-Equity Ratio of Impedimed was 2.39. The lowest was 0.00. And the median was 0.03.
ASX:IPD's Debt-to-Equity is ranked worse than 95.47% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs ASX:IPD: 2.39
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Impedimed Debt-to-Equity Related Terms
Impedimed Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Impedimed's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IPD vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Impedimed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Impedimed's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a Debt-to-Equity of 2.39 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Impedimed and its competitors. This is 7867% above median its historical median of 0.03. According to the industry distribution chart, Impedimed ranks #674 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 95.5%.
Is Impedimed's Debt-to-Equity too high?
Impedimed's current Debt-to-Equity of 2.39 is 7867% above median its 10-year median of 0.03. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Impedimed's value of 2.39 is 962.2% above this industry median. Based on the distribution chart, Impedimed ranks #674 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Impedimed's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #674 out of 706 companies for Debt-to-Equity. This places Impedimed in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Impedimed's value of 2.39 is 962.2% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.23, Impedimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impedimed's current Debt-to-Equity of 2.39 is 962.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current Debt-to-Equity is 2.39, which is 7867% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.8% below its estimated fair value. The current Debt-to-Equity is 2.39, which is 7867% above median its 10-year median of 0.03 and 962.2% above the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Debt-to-Equity is 2.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 
